FDA Warning Letter · #728278
DrMedHealth: FDA Warning Letter (June 8, 2026)
Legal name: Public Health Solution LLC
DrMedHealth received this warning letter on June 8, 2026, from FDA’s Center for Drug Evaluation and Research (CDER). What it cites, and FDA’s own words where we matched them against the letter, are summarized below.
Primary Source
View the original FDA letter on fda.gov →
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/public-health-solution-llc-dba-drmedhealth-728278-06082026
Summary
- Company
- Public Health Solution LLC (dba DrMedHealth)
- Letter number
- #728278
- Issue date
- June 8, 2026
- Subject
- False & Misleading Claims/Misbranded (Telehealth)
What FDA cited
FDA's letter of June 8, 2026 cites DrMedHealth for false or misleading claims about the drugs it sells, under the subject line "False & Misleading Claims/Misbranded (Telehealth)". The GLP-1 drugs it names: semaglutide and tirzepatide.
Your representations regarding compounded semaglutide and tirzepatide products are false or misleading. … Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.
How this letter sits against the other 159
Our reading, from the 160 letters on this register — not part of the FDA’s document.
The FDA issued 25 of the 160 letters on this register on the same day, June 8, 2026. This company was part of a sweep rather than singled out. That does not make the letter less serious, but it does mean the agency was acting against a practice across the market, not against one seller's conduct alone.
DrMedHealth has since stopped selling. Its entry in this register stays up as a record of what it sold and when it closed; a warning letter is often part of that history, not the end of it.
A warning letter is the agency putting a company on notice, not a court finding and not a ban. What it is worth to you is in what it alleges, so read the original on fda.gov rather than the fact that one exists.
For how this charge fits the wider run of GLP-1 letters: What the FDA's GLP-1 warning letters say about this market.
FDA’s letter of June 8, 2026 to Ready Med also cites its recipient for false or misleading claims about the drugs it sells.
From the letter
Read full letter on FDA.gov →Word for word, from the letter of June 8, 2026
This letter notifies you of our concerns and provides you an opportunity to address them. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration. If you cannot completely address this matter within fifteen (15) business days, state the reason for the delay and the time within which you will do so.
If you are not located in the U.S., please note that drug products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your drug products referenced above appear to be misbranded drug products that cannot be legally sold to consumers in the U.S.
1 The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FD&C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and/or because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FD&C Act [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.
Quoted word for word from the U.S. Food and Drug Administration. We assert nothing beyond what the agency published, and the full letter is at https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/public-health-solution-llc-dba-drmedhealth-728278-06082026
What FDA warning letters mean
It is the agency writing to a company to say it believes something that company is doing breaks the Federal Food, Drug, and Cosmetic Act — usually a claim on a website, a labeling choice, or how a drug is being made. The company has about fifteen working days to write back.
Read carefully what it is not. It is not a recall, not a criminal charge, and not a court deciding anyone broke the law. It is the regulator opening a file. Companies frequently answer a letter, fix what was cited, and carry on trading, and when FDA accepts that it can issue a close-out letter. We do not track close-outs, so the presence of a letter on this page tells you what FDA said on one date — not where the matter stands today. Ask the company; they will usually tell you, and how they answer is informative in itself.
Across this market the same three citations recur: claiming a compounded product is equivalent to an approved one, labeling that misleads, and compounding from bulk substances FDA has not cleared under sections 503A and 503B. If you are reading a letter here, it is probably one of those.
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Collective
Flat any-dose pricing, if you can absorb a $199 annual membership on top
From $59/mo + membership
Get started →Embody
A flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies
From $79/mo
Get started →Luvo Health
Moving between compounded and brand without changing seller
From $179/mo
Get started →Other warning letters in our database
- NuScience Peptides LLC — August 24, 2026
- AM RX — June 8, 2026
- Medica Weight Loss — June 8, 2026
- VivioMD — June 8, 2026
- Cosmo Med Spa — September 9, 2025
Editorial Disclaimer
This is a public communication from a regulator, and by itself it settles nothing about whether the company broke any law. Corrective action is a common response, and a fair number of letters end in a close-out. Read the whole thing on fda.gov through the link above rather than taking our excerpt as the full picture.
Glossary
The words sellers use, defined. Tap any term.
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- 503B outsourcing facility · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- FDA Warning Letter · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory